|
Synonyms: ILV-094
Compound class:
Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab [1]. |
| Bioactivity Comments |
| Fezakinumab shows cross-species reactivity, blocking IL-22 receptor activation and cellular proliferation induced by murine, monkey and rat IL-22 in addition to the human cytokine [1]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
